US Pharma MarketingRegeneron sees a future combining its obesity drug with lipid-lowering therapy
Regeneron plans to pair its Hansoh-licensed obesity drug olatorepatide with Praluent, betting lipid control beats ever-higher weight loss. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
MILAN — As more GLP-1-based drugs reach late-stage trials and post stronger and stronger weight loss effects, companies that want to enter the market are looking for differentiating factors.
Regeneron has hit on something new and ...
Source: Endpoints News